| 1 |
34783124 | Ginsenoside RG1 augments doxorubicin-induced apoptotic cell death in MDA-MB-231 breast cancer cell lines. | 2022 Jan |
1 |
| 2 |
35039569 | Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma. | 2022 Jan 17 |
1 |
| 3 |
35209071 | Inhibitory Effect of Ursolic Acid on the Migration and Invasion of Doxorubicin-Resistant Breast Cancer. | 2022 Feb 14 |
1 |
| 4 |
35395977 | [Effect of Doxycycline on Intrinsic Apoptosis of Myeloma Cell Line H929 and Its Mechanism]. | 2022 Apr |
1 |
| 5 |
33115283 | Combination treatment strategies with a focus on rosiglitazone and adriamycin for insulin resistant liver cancer. | 2021 Mar |
1 |
| 6 |
33771646 | Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. | 2021 Aug |
2 |
| 7 |
34119884 | Urinary exosomes-based Engineered Nanovectors for Homologously Targeted Chemo-Chemodynamic Prostate Cancer Therapy via abrogating EGFR/AKT/NF-kB/IkB signaling. | 2021 Aug |
1 |
| 8 |
34232382 | Eukaryotic initiation factor-2, gamma subunit, suppresses proliferation and regulates the cell cycle via the MAPK/ERK signaling pathway in acute myeloid leukemia. | 2021 Nov |
2 |
| 9 |
34238921 | Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. | 2021 Jul 8 |
1 |
| 10 |
34520240 | Retraction of: miR-132 Regulates Adriamycin Resistance in Colorectal Cancer Cells Through Targeting Extracellular Signal-Regulated Kinase 1 (doi: 10.1089/cbr.2018.2749). | 2021 Oct |
1 |
| 11 |
34589399 | Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK signaling pathway. | 2021 Sep |
3 |
| 12 |
31843629 | Parameritannin A-2 from Urceola huaitingii enhances doxorubicin-induced mitochondria-dependent apoptosis by inhibiting the PI3K/Akt, ERK1/2 and p38 pathways in gastric cancer cells. | 2020 Jan 25 |
4 |
| 13 |
32354131 | Early Moderate Intensity Aerobic Exercise Intervention Prevents Doxorubicin-Caused Cardiac Dysfunction Through Inhibition of Cardiac Fibrosis and Inflammation. | 2020 Apr 28 |
1 |
| 14 |
32459053 | BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma. | 2020 Jun |
1 |
| 15 |
32722178 | The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. | 2020 Jul 24 |
1 |
| 16 |
32818507 | EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines. | 2020 Oct 15 |
1 |
| 17 |
31356549 | Curdione Ameliorated Doxorubicin-Induced Cardiotoxicity Through Suppressing Oxidative Stress and Activating Nrf2/HO-1 Pathway. | 2019 Aug |
1 |
| 18 |
31377057 | Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-β in Adriamycin-induced glomerulosclerosis. | 2019 Oct |
1 |
| 19 |
28295305 | Mitochondrial ROS-induced ERK1/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity. | 2018 Jan |
2 |
| 20 |
29108991 | SETDB1-mediated FosB regulation via ERK2 is associated with an increase in cell invasiveness during anticancer drug treatment of A549 human lung cancer cells. | 2018 Jan 1 |
1 |
| 21 |
29307829 | Blockage of cytosolic phospholipase A2 alpha sensitizes aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases. | 2018 Jan 29 |
1 |
| 22 |
29574069 | Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition. | 2018 Jun |
2 |
| 23 |
30230033 | Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway. | 2018 Dec |
1 |
| 24 |
27649518 | Inhibition of the PI3K/AKT Pathway Sensitizes Oral Squamous Cell Carcinoma Cells to Anthracycline-Based Chemotherapy In Vitro. | 2017 Sep |
2 |
| 25 |
28027688 | Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. | 2017 Dec |
1 |
| 26 |
28098907 | Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo. | 2017 Mar |
4 |
| 27 |
28229963 | Constitutively activated ERK sensitizes cancer cells to doxorubicin: Involvement of p53-EGFR-ERK pathway. | 2017 Mar |
3 |
| 28 |
28793338 | Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5. | 2017 |
2 |
| 29 |
28923539 | Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy. | 2017 Nov |
1 |
| 30 |
28988530 | Hyperexpression of Integrin α5β1 Promotes Resistance of MCF-7 Human Breast Carcinoma Cells to Doxorubicin via ERK Protein Kinase Down-regulation. | 2017 Sep |
2 |
| 31 |
29061787 | (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways. | 2017 Nov |
3 |
| 32 |
26842910 | MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). | 2016 Feb 3 |
1 |
| 33 |
25742496 | Correction: Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway. | 2015 |
1 |
| 34 |
24407515 | Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. | 2014 |
1 |
| 35 |
24797310 | Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. | 2014 May 15 |
1 |
| 36 |
24830744 | Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. | 2014 |
1 |
| 37 |
25043687 | Down-regulation of the P-glycoprotein relevant for multidrug resistance by intracellular acidification through the crosstalk of MAPK signaling pathways. | 2014 Sep |
1 |
| 38 |
25268131 | Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway. | 2014 |
2 |
| 39 |
23320839 | MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma. | 2013 Jan 15 |
2 |
| 40 |
23994249 | Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. | 2013 Oct 25 |
1 |
| 41 |
24147064 | Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. | 2013 |
1 |
| 42 |
24217648 | Doxorubicin caused apoptosis of mesenchymal stem cells via p38, JNK and p53 pathway. | 2013 |
1 |
| 43 |
22429871 | A 43 kD protein from the leaves of the herb Cajanus indicus L. modulates doxorubicin induced nephrotoxicity via MAPKs and both mitochondria dependent and independent pathways. | 2012 Jun |
1 |
| 44 |
22457358 | α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). | 2012 May 18 |
3 |
| 45 |
22469513 | Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. | 2012 Jun 15 |
1 |
| 46 |
22493363 | Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs. | 2012 Apr |
1 |
| 47 |
22576950 | Midkine confers Adriamycin resistance in human gastric cancer cells. | 2012 Oct |
6 |
| 48 |
22787275 | Collagen/β1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. | 2012 Sep |
2 |
| 49 |
23028726 | Doxorubicin induces cytotoxicity through upregulation of pERK-dependent ATF3. | 2012 |
3 |
| 50 |
23493035 | Different Expression of Extracellular Signal-Regulated Kinases (ERK) 1/2 and Phospho-Erk Proteins in MBA-MB-231 and MCF-7 Cells after Chemotherapy with Doxorubicin or Docetaxel. | 2012 Jan |
4 |